AJMC October 3, 2022
Allison Inserro

One of the first parts of the landmark Inflation Reduction Act took effect Monday; it boosts the add-on payment for qualifying biosimilars whose average sales price is not more than the price of its reference product from 6% of the reference product’s ASP to 8% for 5 years.

Temporary Medicare Part B payment changes went into effect Monday for the implementation of certain biosimilars, HHS said.

It is one of the first provisions of the Inflation Reduction Act (IRA) to start, and it is part of a strategy to increase access to lower-cost biosimilars, as well as to encourage competition between biosimilars and originator biologics, in the hopes of lowering overall drug costs and creatting savings for beneficiaries and the...

Today's Sponsors

Teladoc Health

Today's Sponsors

Teladoc Health

Today's Sponsor

Oliver Wyman

Topics: Biotechnology, CMS, Govt Agencies, Insurance, Medicare, Pharma / Biotech
SCAN CEO Jain: Don’t Glorify Fee-for-Service to Improve Medicare Advantage
Lawmakers seek to bolster Medicare, Medicaid mental health coverage
Potentially Preventable Hospitalizations of Medicare-Eligible Skilled Nursing Facility Residents
Medicare Advantage in the headlines: 9 recent updates
How Much of an “Advantage” Is Medicare Advantage?